TECLens has commenced the first-in-human clinical trial assessing its quantitative corneal crosslinking (qCXL) technology for non-invasive refractive vision correction, administering treatment to the initial patient.
The qCXL platform aims to strengthen the cornea without removing tissue, marking a step forward in refractive vision correction.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The clinical trial will assess the efficacy and safety of the proprietary CXLens system, which delivers patterned ultraviolet (UV) light to reshape the cornea while maintaining the integrity of the epithelium.
Unlike conventional surgical methods that cut or remove corneal tissue, qCXL technology creates targeted molecular bonds in specific areas of the cornea, strengthening it and resulting in reshaping to improve vision.
The system employs a customised treatment planning engine and real-time ultrasound monitoring for precision.
The ongoing study will primarily focus on patients with refractive errors, especially those affected by presbyopia, a condition impacting around two billion people worldwide.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe non-invasive, epithelium-on treatment is performed in-office, providing new flexibility for patients and physicians.
TECLens CEO Thomas Dunlap said: “This first-in-human trial represents a transformative moment not just for TECLens, but for the field of vision correction as a whole.
“We’re introducing an entirely new category in ophthalmology by bringing vision correction out of the operating room and into the exam room, without surgery.
“Our qCXL technology has the potential to expand treatment options for millions of patients as a first-line treatment for vision correction for both refractive errors and presbyopia.”
TECLens develops non-invasive quantitative corneal crosslinking technology for vision correction. Its CXLens system uses patterned UV light to reshape the cornea with continuous biomechanical control.
The company receives funding from investors, including Johnson & Johnson Innovation – JJDC, Rimonci Capital, Sunmed Capital, and Yonjin Venture.
